Benzinga | Dec 15, 2021 06:24AM EST

Goldman Sachs Initiates Coverage On Athira Pharma with Neutral Rating, Announces Price Target of $16

Goldman Sachs analyst Corinne Jenkins initiates coverage on Athira Pharma (NASDAQ:ATHA) with a Neutral rating and announces Price Target of $16.